A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.

Trial Profile

A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 May 2014

At a glance

  • Drugs Gemcitabine elaidate (Primary) ; Cisplatin
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Feb 2013 Status changed from suspended to discontinued, based on a Clavis Pharma media release.
    • 13 Nov 2012 Status changed from active, no longer recruiting to suspended, as reported in a Clovis Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top